Lakefront Biotherapeutics American Depositary Shares (LKFT) Stock Price, News & Analysis

Company Overview

Galapagos NV (NASDAQ:GLPG) is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company’s discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.

The company’s pipeline encompasses multiple programs across various stages of development. Its lead asset, filgotinib—a selective JAK1 inhibitor—was developed in collaboration with Gilead Sciences for the treatment of rheumatoid arthritis, ankylosing spondylitis and inflammatory bowel disease. In addition to filgotinib, Galapagos is advancing compounds targeting osteoarthritis, idiopathic pulmonary fibrosis and APOL1-mediated kidney disease, with several candidates currently in Phase 2 and Phase 3 clinical trials.

Galapagos maintains strategic partnerships and licensing agreements to extend its research capabilities and global reach. In 2019, the company entered into a collaboration and license agreement with Gilead Sciences, which included an equity investment and options on select pipeline programs. Galapagos also collaborates with Servier, a French pharmaceutical company, to co-develop and commercialize multiple anti-inflammatory programs in Europe and other territories. Its clinical study sites and research facilities span Europe and the United States, reflecting a commitment to conducting trials and manufacturing operations in key markets.

Leadership at Galapagos is headed by Chief Executive Officer Paul Stoffels, who joined the company in 2020 after serving as Chief Scientific Officer at Johnson & Johnson. Under Stoffels’ direction, Galapagos has emphasized precision medicine and accelerated development timelines. The company employs a multidisciplinary team of scientists, clinicians and regulatory specialists, reinforcing its mission to translate genetic insights into first-in-class and best-in-class therapies for patients worldwide.

Key Stats

• Today's Range: $28.18 to $28.69
• 50-Day Range: $26.61 to $32.53
• 52-Week Range: $26.42 to $37.78
• Volume: 117,842 shs
• Average Volume: 154,858 shs
• Market Capitalization: $1.87 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $36.50
• Consensus Rating: Hold

Lakefront Biotherapeutics American Depositary Shares Stock Analysis - MarketRank™

Lakefront Biotherapeutics American Depositary Shares scored higher than 52% of companies evaluated by MarketBeat, and ranked 606th out of 870 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Hold

Consensus Rating

Lakefront Biotherapeutics American Depositary Shares has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 strong buy rating, no buy ratings, 5 hold ratings, and 2 sell ratings.

Upside Potential

Lakefront Biotherapeutics American Depositary Shares has a consensus price target of $36.50, representing about 28.7% upside from its current price of $28.35.

Amount of Analyst Coverage

Lakefront Biotherapeutics American Depositary Shares has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Lakefront Biotherapeutics American Depositary Shares are expected to grow in the coming year, from ($6.32) to ($2.70) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Lakefront Biotherapeutics American Depositary Shares is -20.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Lakefront Biotherapeutics American Depositary Shares is -20.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Lakefront Biotherapeutics American Depositary Shares has a P/B Ratio of 0.49. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

2.51% of the float of Lakefront Biotherapeutics American Depositary Shares has been sold short.

Short Interest Ratio / Days to Cover

Lakefront Biotherapeutics American Depositary Shares has a short interest ratio ("days to cover") of 9.39.

Change versus previous month

Short interest in Lakefront Biotherapeutics American Depositary Shares has recently increased by 11.65%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Lakefront Biotherapeutics American Depositary Shares does not currently pay a dividend.

Dividend Growth

Lakefront Biotherapeutics American Depositary Shares does not have a long track record of dividend growth.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.61

News Sentiment

Lakefront Biotherapeutics American Depositary Shares has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.83 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Lakefront Biotherapeutics American Depositary Shares this week, compared to 3 articles on an average week.

MarketBeat Follows

1 people have added Lakefront Biotherapeutics American Depositary Shares to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Lakefront Biotherapeutics American Depositary Shares insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.91% of the stock of Lakefront Biotherapeutics American Depositary Shares is held by insiders.

Percentage Held by Institutions

32.46% of the stock of Lakefront Biotherapeutics American Depositary Shares is held by institutions.

Company Calendar

• Last Earnings: 2/15/2026
• Today: 5/31/2026
• Next Earnings (Estimated): 8/10/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:LKFT
• Previous Symbol: NASDAQ:GLPG
• CIK: 1421876
• Web: www.glpg.com
• Phone: (321) 534-2900
• Fax: 321-534-2901
• Employees: 1,310
• Year Founded: 1999

Price Target and Rating

• Average Price Target for Lakefront Biotherapeutics American Depositary Shares: $36.50
• High Price Target: $40.00
• Low Price Target: $33.00
• Potential Upside/Downside: +28.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 30.48
• Quick Ratio: 30.30

Sales & Book Value

• Annual Sales: $1.26 billion
• Price / Sales: 1.49
• Cash Flow: $0.73 per share
• Price / Cash Flow: 39.05
• Book Value: $57.78 per share
• Price / Book: 0.49

Miscellaneous

• Outstanding Shares: 65,900,000
• Free Float: 63,979,000
• Market Cap: $1.87 billion
• Optionable: Optionable
• Beta: 0.25